--- title: "TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement" type: "News" locale: "en" url: "https://longbridge.com/en/news/286833781.md" description: "TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans." datetime: "2026-05-18T23:25:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286833781.md) - [en](https://longbridge.com/en/news/286833781.md) - [zh-HK](https://longbridge.com/zh-HK/news/286833781.md) --- # TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An update from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has launched a placement of 3,836,000 new H shares at HK$40.83 each, representing about 1.24% of its existing H-share capital, under its existing general mandate. The shares, to be allocated to at least six institutional and professional investors at an 18% discount to recent market prices, will modestly dilute existing holders while broadening the shareholder base. The placement is expected to raise gross proceeds of roughly HK$156.62 million and net proceeds of about HK$152.13 million, with a net issue price of approximately HK$39.66 per share. As the deal is on a best-effort basis and subject to conditions and regulatory approvals, the transaction may not complete, leaving investors alert to execution risk as the company seeks fresh capital for its ongoing operations and strategic plans. **More about TransThera Sciences (Nanjing). Inc.** TransThera Sciences (Nanjing), Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2617. The company operates in the biopharmaceutical sector and accesses international capital markets through H-share issuances to support its research, development and commercialization activities. **Average Trading Volume:** 2,500,535 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** HK$15B Find detailed analytics on 2617 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159748.CN](https://longbridge.com/en/quote/159748.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [02617.HK](https://longbridge.com/en/quote/02617.HK.md) ## Related News & Research - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)